Supernus Pharmaceuticals Comprehensive Income 2011-2024 | SUPN
Supernus Pharmaceuticals comprehensive income from 2011 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Supernus Pharmaceuticals Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-1 |
| 2022 |
$-3 |
| 2021 |
$2 |
| 2020 |
$9 |
| 2019 |
$7 |
| 2018 |
$-3 |
| 2017 |
$-1 |
| 2016 |
$-0 |
| 2015 |
$-0 |
| 2014 |
$-0 |
| 2013 |
$0 |
| 2012 |
$-0 |
| 2011 |
$0 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Comprehensive Income
(Millions of US $) |
| 2024-06-30 |
$-0 |
| 2024-03-31 |
$-1 |
| 2023-12-31 |
$-1 |
| 2023-09-30 |
$-1 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-3 |
| 2022-09-30 |
$-4 |
| 2022-06-30 |
$-2 |
| 2022-03-31 |
$-1 |
| 2021-12-31 |
$2 |
| 2021-09-30 |
$4 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$6 |
| 2020-12-31 |
$9 |
| 2020-09-30 |
$10 |
| 2020-06-30 |
$11 |
| 2020-03-31 |
$-0 |
| 2019-12-31 |
$7 |
| 2019-09-30 |
$7 |
| 2019-06-30 |
$6 |
| 2019-03-31 |
$1 |
| 2018-12-31 |
$-3 |
| 2018-09-30 |
$-4 |
| 2018-06-30 |
$-4 |
| 2018-03-31 |
$-2 |
| 2017-12-31 |
$-1 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$-0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$1 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$-0 |
| 2015-09-30 |
$-0 |
| 2015-06-30 |
$-0 |
| 2015-03-31 |
$-0 |
| 2014-12-31 |
$-0 |
| 2014-09-30 |
$-0 |
| 2014-06-30 |
$0 |
| 2014-03-31 |
$0 |
| 2013-12-31 |
|
| 2013-09-30 |
$-0 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
$-0 |
| 2012-12-31 |
$-0 |
| 2012-09-30 |
$-0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$0 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.771B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
